Stem (STEM) Projected to Post Earnings on Wednesday

Stem (NYSE:STEM) is expected to be announcing its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect Stem to post earnings of ($1.76) per share and revenue of $36.6450 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 5:00 PM ET.

Stem Trading Up 0.2%

Shares of STEM opened at $5.89 on Monday. The stock has a 50-day moving average price of $7.07 and a 200-day moving average price of $9.75. The company has a market cap of $52.77 million, a PE ratio of -0.68 and a beta of 1.50. Stem has a 12-month low of $4.92 and a 12-month high of $32.23.

Wall Street Analyst Weigh In

Several brokerages have issued reports on STEM. Wall Street Zen lowered shares of Stem from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Susquehanna decreased their price target on shares of Stem from $10.00 to $7.50 and set a “neutral” rating on the stock in a report on Friday, July 10th. UBS Group restated a “neutral” rating and set a $10.50 price objective (down from $12.00) on shares of Stem in a research report on Monday, May 11th. Barclays dropped their price objective on shares of Stem from $18.00 to $8.00 and set an “equal weight” rating for the company in a report on Monday, July 27th. Finally, Roth Capital reissued a “neutral” rating and issued a $11.00 target price on shares of Stem in a research note on Thursday, May 7th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $9.00.

Stem News Summary

Here are the key news stories impacting Stem this week:

• Neutral Sentiment: Research reports examined neural stem-cell development, including the early separation of neuron lineages and two parallel programs involved in building the brain’s cortex. The findings may be relevant to biotechnology research but do not appear connected to Stem, Inc.’s commercial business. Neural stem cells split early into distinct neuron lineages
• Neutral Sentiment: Additional medical coverage discussed growth-hormone treatment for childhood stem-cell-transplant survivors, improved survival from stem-cell transplants in primary CNS lymphoma, and RNA pathways that could improve future stem-cell therapies. These developments concern healthcare research, not Stem’s energy-storage products. Growth hormone therapy helps childhood stem cell transplant survivors grow taller Stem Cell Transplant Boosts Survival in Primary CNS Lymphoma
• Neutral Sentiment: News about innovation hubs, school STEM laboratories, classroom kits, summer camps, robotics education, and engineering programs reflects broader interest in science and technology education. However, none of the initiatives identifies Stem, Inc. as a participant or customer. Tiny RNA pathway emerges as a powerful lever for the future of stem cell therapy
• Negative Sentiment: With no fresh operating or partnership announcement to offset concerns, investor attention may remain focused on Stem’s weak fundamentals. The company’s latest reported quarter missed both EPS and revenue expectations, while analysts expect a substantial full-year loss, leaving the stock vulnerable to continued pressure.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of STEM. Balyasny Asset Management L.P. bought a new stake in shares of Stem in the 4th quarter valued at about $177,000. Bridgeway Capital Management LLC increased its stake in shares of Stem by 346.2% in the fourth quarter. Bridgeway Capital Management LLC now owns 69,600 shares of the company’s stock worth $1,047,000 after buying an additional 54,000 shares during the period. Trexquant Investment LP bought a new stake in Stem during the 4th quarter valued at $385,000. Jump Financial LLC purchased a new stake in Stem during the 4th quarter valued at $534,000. Finally, Mangrove Partners IM LLC purchased a new stake in Stem during the 4th quarter valued at $272,000. Hedge funds and other institutional investors own 61.63% of the company’s stock.

Stem Company Profile

Stem, Inc is a technology company specializing in AI-driven energy storage and optimization solutions for commercial, industrial and utility customers. The company delivers integrated hardware and software systems that enable clients to manage energy consumption, reduce peak demand charges and provide ancillary services to the power grid. By combining battery storage hardware with advanced machine-learning algorithms, Stem helps organizations align energy usage with cost-saving opportunities while supporting grid reliability and renewable integration.

At the core of Stem’s offering is its Athena software platform, which uses real-time data and predictive analytics to forecast energy needs and automatically dispatch stored energy when it is most valuable.